A Family of Synergistic
Precigen is focused on improving patient care through innovative gene and cell therapies. Our subsidiaries are an important part of realizing this mission as they are advancing a portfolio of unique solutions to address unmet needs in health.
Enabling discovery by providing porcine research models and services that aid scientists in the understanding of human disease mechanisms, development of new therapeutics, development of next-generation medical procedures and devices, and optimization of novel diagnostics.
Precigen’s healthcare assets include wholly-owned subsidiaries PGEN Therapeutics, Precigen ActoBio and Precigen Exemplar, and a majority ownership interest in Precigen Triple-Gene.